EMA In The Clear Over Transparency In COVID-19 Product Assessments
Ombudsman Says Agency Showed ‘High Transparency Standards’
Executive Summary
The European Ombudsman has closed an inquiry into the European Medicines Agency’s practices with regard to coronavirus vaccines and treatments.
You may also be interested in...
Rasi To Ombudsman: No Risk Of Bias In EMA’s COVID-19 Drug Evaluations
European Medicines Agency chief Guido Rasi has responded to questions by the European Ombudsman about its COVID-19 Pandemic Task Force.
EMA Heeds Ombudsman’s Advice On Avoiding Perception Of Bias In Drug Evaluations
An inquiry by the EU Ombudsman has prompted the European Medicines Agency to introduce changes to ensure that its experts, who advise companies in the premarket phase, are not appointed to evaluate marketing applications for the same drugs.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.